1-环丙基-2-苯基乙胺 | 56595-00-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-环丙基-2-苯基乙胺
• 英文名称: Benzylcyclopropylcarbinylamin
• 英文别名: 1-Cyclopropyl-2-phenyl-ethylamin；1-Cyclopropyl-2-phenylethanamine
• CAS: 56595-00-7
• 化学式: C₁₁H₁₅N
• mdl: MFCD11934474
• 分子量: 161.247
• InChiKey: KWHUZILRMHTFDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 1-环丙基-2-苯基乙胺 以 甲酸 为溶剂， 生成 Benzylcyclopropylcarbinyldimethylamin
  参考文献：
  名称：

  Sommelet-Hauser Rearrangement of Allylbenzyldimethylammonium Bromide and Cyclopropylcarbinylbenzyldimethylammonium Bromide. Evidence for Carbanion Stabilization by the Cyclopropane Ring

  摘要：

  DOI：

  10.1021/ja00884a015
• 作为产物：
  描述：

  1-环丙基-2-苯乙酮 在 甲酸铵 作用下， 生成 1-环丙基-2-苯基乙胺
  参考文献：
  名称：

  Cussac; Boucherle; Hache, European Journal of Medicinal Chemistry, 1975, vol. 10, # 2, p. 112 - 116

  摘要：

  DOI：

文献信息

• [EN] CXCR7 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR DE CXCR7
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014191929A1

  公开（公告）日：2014-12-04

  The present invention relates to derivatives of formula (I) Formula (I) wherein (R1)n, R 2a, R 2b, R 3a, R 3b, R 4, L1, L2, X, Y and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

  本发明涉及公式（I）的衍生物 公式（I）其中（R1）n，R 2a，R 2b，R 3a，R 3b，R 4，L1，L2，X，Y 和 Ar1 如描述中所述，其制备方法，其药学上可接受的盐，以及其作为药物的用途，含有一个或多个公式（I）化合物的药物组合物，特别是其作为CXCR7受体调节剂的用途。
• [EN] NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS<br/>[FR] NOUVEAUX DERIVES DE TETRAHYDROPYRIDINE EN TANT QU'INHIBITEURS DE RENINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2004002957A1

  公开（公告）日：2004-01-08

  The invention relates to novel tetrahydropyridine derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

  该发明涉及新型四氢吡啶衍生物及相关化合物，以及它们作为药物组合物中活性成分的用途。该发明还涉及相关方面，包括制备这些化合物的过程、含有其中一个或多个这些化合物的药物组合物，特别是它们作为肾素抑制剂的用途。
• [EN] 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES<br/>[FR] DERIVES DE 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE RENINE DANS LE TRAITEMENT DE L'HYPERTENSION, DE MALADIES CARDIOVASCULAIRES OU RENALES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2003093267A1

  公开（公告）日：2003-11-13

  The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivatives of formula (I) and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors or renin.

  该发明涉及新型3,9-二氮杂双环[3.3.1]壬烯衍生物（I）及相关化合物，以及它们作为药物组合物中活性成分的用途。该发明还涉及相关方面，包括制备这些化合物的过程、含有这些化合物中的一个或多个的药物组合物，尤其是它们作为肾素抑制剂的用途。
• N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use
  申请人：Chu Shao Song

  公开号：US20050101595A1

  公开（公告）日：2005-05-12

  Aminothiazole compounds with N-containing cycloalkyl at the 2-amino position which are represented by the Formula (I), or a pharmaceutically acceptable prodrug of said compound, pharmaceutically active metabolite or pharmaceutically acceptable salt of said compound, or metabolite thereof, modulate and/or inhibit the cell proliferation and activity of protein kinases. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.

  公式（I）所代表的在2-氨基位置带有含氮环烷基的氨基噻唑化合物，或该化合物的药物可接受的前药、药理活性代谢物或药物可接受的盐，或其代谢物，可以调节和/或抑制蛋白激酶的细胞增殖和活性。本发明还涉及含有这种化合物的制药组合物的治疗或预防用途，以及通过给予这种化合物的有效量来治疗恶性肿瘤和其他疾病的方法。
• 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases
  申请人：Bezencon Olivier

  公开号：US20050176700A1

  公开（公告）日：2005-08-11

  The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivatives of formula (I) and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors or renin.

  本发明涉及式(I)的新型3,9-二氮杂双环[3.3.1]壬烯衍生物及其相关化合物，以及它们作为药物组分在制备药物组合物中的应用。本发明还涉及相关方面，包括制备这些化合物的过程、含有其中一个或多个这些化合物的药物组合物，尤其是它们作为肾素抑制剂的应用。